Overview of the Phase II Clinical Trial
At a recent global health conference, exciting results were presented concerning the Phase II clinical trial of iruplinalkib tablets, also known as Qixinke. This trial, named the INTELLECT study, focused on the impact of the drug on patients suffering from anaplastic lymphoma kinase (ALK)-positive crizotinib-resistant non-small-cell lung cancer (NSCLC).
What is Iruplinalkib?
Iruplinalkib, developed by Qilu Pharmaceutical, is a cutting-edge ALK/ROS1 kinase inhibitor. It received approval from the NMPA in June 2023 for the treatment of patients with ALK-positive locally advanced or metastatic NSCLC who have experienced disease progression after crizotinib therapy or could not tolerate its side effects. Earlier this year, it was also authorized for first-line treatment of ALK-positive NSCLC.
Leadership and Findings of the Study
The study was led by Prof. Yuankai Shi from the Cancer Hospital of the Chinese Academy of Medical Sciences & Peking Union Medical College, and it has made notable advancements. Preliminary data was first published in BMC Medicine in 2023, and the findings were presented at the conference following an extensive two-year follow-up.
Participants and Survival Statistics
The INTELLECT study included 146 participants, offering valuable insights into the treatment's effectiveness. At the time of the last follow-up, participants had a median follow-up period of 42.41 months, revealing a median overall survival (OS) rate of 41.79 months. Additionally, the trial reported an objective response rate (ORR) of 63.7% and an impressive disease control rate (DCR) of 94.5%. The study also noted median duration of response (DoR) and median progression-free survival (PFS) at 14.06 months and 14.55 months, respectively.
Effects on Patients with CNS Metastasis
A closer examination of 90 patients with CNS metastasis at the study's start showed an ORR of 55.6% and a DCR of 93.3%. The median values for DoR and PFS were recorded at 17.25 months, while the median OS reached 43.01 months.
Intracranial Responses and Safety Profile
The study utilized RECIST v1.1 criteria, reporting an 18.9% intracranial complete response (CR) among patients who initially had CNS metastasis. In a subgroup of 42 patients with measurable intracranial lesions, an intracranial objective response rate (iORR) of 64.3% and an iDCR of 95.2% were documented.
Regarding safety, the trial noted a high rate of treatment-related adverse events (TRAEs) at 93.8%, with 30.8% classified as grade 3 or 4. Common TRAEs included increases in aspartate aminotransferase, hypercholesterolemia, and elevated alanine aminotransferase levels. Importantly, no new safety signals were identified during this study.
Long-term Advantages of Iruplinalkib
The long-term follow-up from the INTELLECT trial emphasized that iruplinalkib provides significant overall survival benefits for patients with advanced NSCLC resistant to crizotinib, all while maintaining a strong safety profile.
Frequently Asked Questions
What is iruplinalkib?
Iruplinalkib is a next-generation ALK/ROS1 kinase inhibitor designed specifically for treating ALK-positive non-small-cell lung cancer.
What were the key findings from the Phase II clinical trial?
The trial revealed a median overall survival of 41.79 months, alongside high rates of objective response and disease control, while also demonstrating a manageable safety profile.
Who led the INTELLECT study?
The INTELLECT study was led by Prof. Yuankai Shi from the Cancer Hospital of the Chinese Academy of Medical Sciences & Peking Union Medical College.
Is iruplinalkib approved for use?
Yes, iruplinalkib has received approval from the NMPA for the treatment of patients with advanced ALK-positive NSCLC.
What are the treatment-related adverse events associated with iruplinalkib?
Common adverse events include elevated liver enzymes and hypercholesterolemia; however, no new safety signals were detected during the study.
